Aytu BioPharma, Inc.AYTUNASDAQ
Loading
Free Cash Flow Growth AcceleratingAccelerating
Percentile Rank100
3Y CAGR+111.3%
5Y CAGR+61.3%
Year-over-Year Change
Year-over-year free cash flow growth rate
3Y CAGR
+111.3%/yr
vs +117.6%/yr prior
5Y CAGR
+61.3%/yr
Recent acceleration
Acceleration
-6.3pp
Decelerating
Percentile
P100
Near historical high
vs 5Y Ago
10.9x
Strong expansion
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 691.91% |
| Q3 2025 | -122.18% |
| Q2 2025 | 142.70% |
| Q1 2025 | -325.04% |
| Q4 2024 | 318.63% |
| Q3 2024 | -18.71% |
| Q2 2024 | -339.76% |
| Q1 2024 | -88.15% |
| Q4 2023 | 36.02% |
| Q3 2023 | -102.25% |
| Q2 2023 | 422.26% |
| Q1 2023 | -19.10% |
| Q4 2022 | 73.33% |
| Q3 2022 | -28.94% |
| Q2 2022 | 22.16% |
| Q1 2022 | -3.32% |
| Q4 2021 | -132.71% |
| Q3 2021 | 39.69% |
| Q2 2021 | 28.38% |
| Q1 2021 | -200.19% |
| Q4 2020 | 63.37% |
| Q3 2020 | -2.81% |
| Q2 2020 | 32.61% |
| Q1 2020 | -88.91% |
| Q4 2019 | -104.14% |
| Q3 2019 | 5.86% |
| Q2 2019 | 5.46% |
| Q1 2019 | 22.10% |
| Q4 2018 | -41.27% |
| Q3 2018 | 32.86% |
| Q2 2018 | -9.72% |
| Q1 2018 | -33.01% |
| Q4 2017 | 26.19% |
| Q3 2017 | -26.77% |
| Q2 2017 | -38.58% |
| Q1 2017 | 16.53% |
| Q4 2016 | 46.11% |
| Q3 2016 | -13.21% |
| Q2 2016 | -91.33% |
| Q1 2016 | 31.01% |